Association between rheumatoid arthritis and urinary tract infections caused by Proteus spp.: a review
DOI:
https://doi.org/10.25758/set.2260Keywords:
Rheumatoid arthritis, Urinary tract infections, Proteus spp., Shared epitopeAbstract
Rheumatoid arthritis (RA) is a systemic and arthritic autoimmune disease that affects millions of people worldwide. The World Health Organization has reinforced its concerns regarding RA morbidity. Characterized by inflammation of the joints which can lead to the destruction of the periarticular tissue, causing pain and joint deformities. During the last four decades, scientific data has suggested that urinary tract infections (UTI) caused by Proteus spp. have a key role in the aetiopathogenesis of RA. Here, we performed a qualitative systematic review of the available literature regarding the association between RA and UTI caused by Proteus spp. from a worldwide perspective. We selected four studies that either show increased isolation of Proteus spp. in the urine of patients with RA or show elevated levels of anti-Proteus antibodies in the serum of RA patients, of the population of different countries from three continents, always comparing with healthy and/or non-RA disease controls. This work reinforces the evidence linking Proteus spp. to RA, from the recurrent sub-clinical Proteus UTIs to the full development of RA. Antimicrobial susceptibility testing guided therapy must be considered crucial to ensure therapeutic success and prevent or minimize the occurrence of RA associated with UTI and future research should be performed with the aim to access if the usage of antibiotics against Proteus spp. from the urinary tract could be implemented as adjuvant therapies to treat RA. Additionally, due to the fact that no research regarding the described association has been performed in Portugal, we suggest the development of a future research project, to access if the Portuguese population follows the trend of the countries referred to in this review.
Downloads
References
Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):347-57.
Centers for Disease Control and Prevention. Rheumatoid arthritis (RA) [homepage]. National Center for Chronic Disease Prevention and Health Promotion; 2019 [updated 2020 Jul 27]. Available from: https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38.
Jinno S, Lu N, Jafarzadeh SR, Dubreuil M. Trends in hospitalizations for serious infections in patients with rheumatoid arthritis in the US between 1993 and 2013. Arthritis Care Res. 2018;70(4):652-8.
World Health Organization. Chronic rheumatic conditions [homepage]. Geneva: WHO; [s.d.]. Available from: http://www.who.int/chp/topics/rheumatic/en/
Luís M, Freitas J, Costa F, Buttgereit F, Boers M, Da Silva J, et al. An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2019;18(7):581-90.
Senior BW, Anderson GA, Morley KD, Kerr MA. Evidence that patients with rheumatoid arthritis have asymptomatic ‘non-significant’ Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect. 1999;38(2):99-106.
Wilson C, Thakore A, Isenberg D, Ebringer A. Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int. 1997;16(5):187-9.
Ebringer A, Rashid T. Rheumatoid arthritis is caused by a Proteus urinary tract infection. APMIS. 2014;122(5):363-8.
Joo YB, Lim YH, Kim KJ, Park KS, Park YJ. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):199.
Puntis D, Malik S, Saravanan V, Rynne M, Heycock C, Hamilton J, et al. Urinary tract infections in patients with rheumatoid arthritis. Clin Rheumatol. 2013;32(3):355-60.
Kumar S, Dave A, Wolf B, Lerma EV. Urinary tract infections. Dis Mon. 2015;61(2):45-59.
World Health Organization. WHO model prescribing information: drugs used in bacterial infections. Geneva: WHO; 2001.
CUF. Infeção urinária [Internet]. CUF; [s.d.]. Available from: https://www.saudecuf.pt/mais-saude/doencas-a-z/infecao-urinaria
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
Drzewiecka D. Significance and roles of Proteus spp. bacteria in natural environments. Microb Ecol. 2016;72(4):741-58.
Belas R, Schneider R, Melch M. Characterization of Proteus mirabilis precocious swarming mutants: identification of rsbA, encoding a regulator of swarming behavior. J Bacteriol. 1998;180(23):6126-39.
Armbruster CE, Mobley HL, Pearson MM. Pathogenesis of Proteus mirabilis infection. EcoSal Plus. 2018;8(1).
Schaffer JN, Pearson MM. Proteus mirabilis and urinary tract infections. Microbiol Spectr. 2015;3(5).
Ebringer A, Rashid T. Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection. Clin Dev Immunol. 2006;13(1):41-8.
Christopoulos G, Christopoulou V, Routsias JG, Babionitakis A, Antoniadis C, Vaiopoulos G. Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis. Clin Rheumatol. 2017;36(3):527-35.
Rashid T, Leirisalo-Repo M, Tani Y, Hukuda S, Kobayashi S, Wilson C, et al. Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. Clin Rheumatol. 2004;23(2):134-41.
Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher Jr HR, El-Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology. 2005;44(11):1433-41.
Wilson C, Rashid T, Ebringer A. Worldwide links between Proteus mirabilis and rheumatoid arthritis. J Arthritis. 2015;4(1):1000142.
Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect. 2003;46(2):94-100.
Hayami H, Takahashi S, Ishikawa K, Yasuda M, Yamamoto S, Uehara S, et al. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother. 2013;19(3):393-403.
Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents. 2011;37(3):210-8.
Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis. 2003;45(4):295-301.
Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-3.
Kantele A, Papunen R, Virtanen E, Möttönen T, Räsänen L, Ala-Kaila K, et al. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response. J Infect Dis. 1994;169(5):1023-8.
Trinchieri A, Braceschi L, Tiranti D, Dell’Acqua S, Mandressi A, Pisani E. Secretory immunoglobulin A and inhibitory activity of bacterial adherence to epithelial cells in urine from patients with urinary tract infections. Urol Res. 1990;18(5):305-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Saúde e Tecnologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.
The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).
All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.
